Michael Dixon
Partner @ Sequoia Capital
San Francisco, United States
Michael Dixon is a Series B investor at Sequoia Capital in San Francisco focused on Health Care and Medical. Michael Dixon is based out of San Francisco, California and is a Managing Partner of Transformation Capital.Michael previously worked at Cleo as a Member, Board of Directors .Michael Dixon attended Boston College.
- Total investments:
- 31
- Last investment:
- Lead investor:
- 39%
Last updated:
For AI agents: llms.txt
Industries Michael Dixon invests in
Stages Michael Dixon invests in
Countries Michael Dixon invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 11 (35%)
- Medical 4 (13%)
- Biotechnology 4 (13%)
- Employee Benefits 3 (10%)
- Health Diagnostics 3 (10%)
Stage
- Series B 6 (19%)
- Series C 6 (19%)
- Series D 3 (10%)
- Seed 2 (6%)
- Series A 2 (6%)
Country
- United States 15 (48%)
- Brazil 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Citizen Health is a personalized AI Advocate platform that helps patients understand and organize their medical information. | $30M / Series A / Aug 14, 2025 | ||
| Carecode system combines powerful Generative AI models with continuous learning mechanisms, enabling natural and autonomous interactions that adapt to complicated environments without the need for human intervention. | $4.3M / Pre-Seed / Dec 30, 2024 | ||
| Citizen Health is a personalized AI Advocate platform that helps patients understand and organize their medical information. | $14.5M / Seed / Nov 19, 2024 | ||
| Amino is a healthcare financial wellness platform that helps companies and their employees navigate the complexities of the US healthcare system and find the highest value care, which has become even more important of late. It simplifies high-value healthcare benefits by providing data-driven, individualized care suggestions that plan members willfollow. With a system that benefits patients and everyone, Amino Health makes healthcare more intuitive, accessible, and convenient. | $10M / Venture - Series Unknown / May 22, 2024 | ||
| Citizen Health is a personalized AI Advocate platform that helps patients understand and organize their medical information. | Seed / Dec 13, 2023 | ||
| Amino is a healthcare financial wellness platform that helps companies and their employees navigate the complexities of the US healthcare system and find the highest value care, which has become even more important of late. It simplifies high-value healthcare benefits by providing data-driven, individualized care suggestions that plan members willfollow. With a system that benefits patients and everyone, Amino Health makes healthcare more intuitive, accessible, and convenient. | $38M / Venture - Series Unknown / May 11, 2023 | ||
| At Nayya, we believe there’s a better way to choose and use benefits. A more transparent, less confusing way for employees to control their health and financial potential. Powered by billions of data points and machine learning, our benefits experience platform delivers personalized decision support and guidance during open enrollment, new employeeonboarding, qualifying life events, and in the moments that matter all year round. This is one of the most stressful and challenging situations consumers face – and we see that as an opportunity to build an innovative response that can help millions of Americans possess the control and understanding they deserve. Join the consumers and their employers that are now living with more peace and confidence at Nayya.com. | $55M / Series C / Mar 01, 2022 | ||
| Cleo is the only global, holistic family care platform supporting individuals throughout every life stage. Whether individuals are growing their family, raising children or teenagers, caring for an adult loved one, doing both as part of the growing Sandwich Generation, or taking care of their own health, Cleo provides life-changing care forfamilies and caregivers. This is achieved through advanced analytics, virtual coaching, proactive concierge support, and navigation to community resources and benefits — so families can be happier and healthier both at home and at work. Serving more than 200 clients, Cleo provides global, equitable, and inclusive support with Guides located in every region of the world. With a focus on driving family health outcomes, Cleo provides real-time risk assessment, virtual coaching and concierge support for over 40 evidence-based care journeys called LifePaths, including cancer care, neurodivergence, menopause, and self-care. Cleo is proven to improve mental health and decrease burnout for members — as guaranteed by The Validation Institute — all while maximizing cost savings, increasing productivity, reducing healthcare spend, and improving the health & wellbeing of the family unit.For more information, visit www.hicleo.com. | $40M / Series C / Mar 30, 2021 | ||
| Datavant is a health data platform company. We make the world’s health data secure, accessible, and usable. Datavant drives data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Datavant enables more than 60 million healthcare records to move between thousandsof organizations, more than 70,000 hospitals and clinics, 70% of the 100 largest health systems, and an ecosystem of 500+ real-world data partners.To learn more about Datavant, visit datavant.com. | $40M / Series B / Oct 08, 2020 | ||
| Mustard is an elite-level motion analysis app for broad athletics coaching. Mustard's platform conducts complex data analysis of video captured in-app on a player or coach's mobile phone and delivers easily understandable report cards along with personalized, actionable drills to optimize performance. The robust AI technology andapplication suite, to expand into additional sports, and to build out an elite and robust mental performance training platform for all athletes.Mustard was founded in 2019 by Tom House, Jason Goldsmith, Luke Collis, and Rocky Collis. | $1.7M / Seed / Sep 04, 2020 | ||
| See all 31 investments → | |||
Co-Investors
About Sequoia Capital
Sequoia Capital provides capital alongside strategic guidance, supporting areas such as product development, company building, and market expansion. The firm engages with a limited number of companies at a time, working closely with leadership teams throughout the business lifecycle. Sequoia Capital focuses on long-term partnerships, often entering at the idea or formation stage and remaining involved as companies scale and mature. Its approach emphasizes collaboration among its internal team and portfolio founders, drawing on shared experience to address operational and strategic challenges.
Sequoia Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anas Biad
Partner
|
|||
Andrew Lee
Vice President
|
|||
Carl Eschenbach
Partner
|
|||
Caroline Fu
Vice President
|
|||
Donald Valentine
Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Michael Dixon invest in?
Michael Dixon invests primarily in Health Care, Medical and Biotechnology startups, most often at Series B and Series C stage. Most of the 31 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Michael Dixon?
Public channels for Michael Dixon include LinkedIn and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Michael Dixon last invest?
The most recent investment recorded for Michael Dixon closed in Aug 2025. Shizune tracks 31 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
